![Mark Finn](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Mark Finn
Ordförande på
CALYXTPAR
Förmögenhet: 2 M $ per 2026-05-31
Profil
Mr. Mark T.
Finn is a Chairman at Cibus, Inc., a Chairman, CEO & CCO at Vantage Consulting Group, Inc., a Managing Member at New Ventures I LLC, a Managing Member at New Ventures II LLC and a Managing Member at New Ventures III LLC.
He is on the Board of Directors at Enterin, Inc., Cibus Corp., Cibus Ltd. and Cibus US LLC.
Mr. Finn was previously employed as a Principal by Lindner Asset Management, Inc., a Principal by Virginia National Bank (Charlottesville), a Co-Founder by NEW Ventures LLC, a Co-Founder by New Ventures Select LLC, and a Professor by University of Virginia.
He also served on the board at The RF&P Corp.
He received his MBA from The College of William & Mary.
Kända innehav i offentliga företag
| Företag | Datum | Antal aktier | Värdering | Värderingsdatum |
|---|---|---|---|---|
CIBUS, INC. CLASS A 2,38 % | 2026-06-02 | 1 247 962 ( 2,38 % ) | 2 M $ | 2026-05-31 |
Aktiva positioner av Mark Finn
| Företag | Position | Start |
|---|---|---|
| CALYXT, INC. | Direktör/Styrelseledamot | 2009-01-01 |
| CALYXTPAR | Ordförande | 2025-08-06 |
Cibus US LLC
 Cibus US LLC BiotechnologyHealth Technology Develops products in agriculture and specialty chemicals | Direktör/Styrelseledamot | - |
Cibus Ltd.
 Cibus Ltd. BiotechnologyHealth Technology Engages in the research and development of plant gene editing technology | Direktör/Styrelseledamot | - |
Vantage Consulting Group, Inc.
 Vantage Consulting Group, Inc. Investment ManagersFinance Vantage strives to deliver a comprehensive, bespoke investment solution firmly grounded in fundamental investment principles. At the core of this solution lies an investment strategy meticulously tailored to their clients’ unique investment objectives, risk tolerances, diversification preferences, and their specific liquidity needs and investment horizons. | Verkställande Direktör | 1986-01-01 |
Enterin, Inc.
 Enterin, Inc. BiotechnologyHealth Technology Develops novel compounds that dysfunctional gut-brain axis in patients with neurodegenerative disease | Direktör/Styrelseledamot | 2017-01-01 |
New Ventures I LLC
 New Ventures I LLC Investment ManagersFinance Functions as a venture capital fund | Företagsledare/Principal | - |
New Ventures III LLC
 New Ventures III LLC Investment ManagersFinance Acts as Venture Capital Fund | Företagsledare/Principal | - |
New Ventures II LLC
 New Ventures II LLC Investment ManagersFinance Functions as a venture capital fund | Företagsledare/Principal | - |
Tidigare kända positioner av Mark Finn
| Företag | Position | Slut |
|---|---|---|
| ░░░░░░░ ░░░░░ ░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░ ░░░░░░░░ ░░░ | ░░░░░░░░ | - |
| ░░░ ░░░░░░░░ ░░░░░░ ░░░ | ░░░░░░░░ | - |
| ░░░░░░░░░░ ░░ ░░░░░░░░ | ░░░░░░░░░░░░░░░░░░░░░░░░░ | - |
| ░░░ ░░░░░░░░ ░░░░░ | ░░░░░░░░░░░░░░░░░░░░░░░░░ | - |
Mark Finns utbildningar
Erfarenheter
Innehade positioner
Aktiva
Inaktiva
Börsnoterade företag
Privata företag
Relationer
59
Första gradens relationer
16
Företag kopplade till första graden
Man
Kvinna
Styrelseledamöter
Chefer
Kopplade företag
| Privata företag | 16 |
|---|---|
Lindner Asset Management, Inc.
 Lindner Asset Management, Inc. Investment ManagersFinance Lindner is a mid/large-cap growth manager of managers. Their approach is to offer a diversified family of products through the selection of the optimum manager in each investment strategy. They continually monitor the adherence of the sub-advisors to their prescribed investment criteria. Lindner's ongoing monitoring of the sub-advisors includes tracking of style, performance and risk measurement to the appropriate benchmark and peer group. | Finance |
NEW Ventures LLC
 NEW Ventures LLC Information Technology ServicesTechnology Services Provides information technology services for health industry | Technology Services |
New Ventures I LLC
New Ventures I LLC Investment ManagersFinance Functions as a venture capital fund | Finance |
Cibus Corp.
 Cibus Corp. BiotechnologyHealth Technology Operates as an agricultural technology company that develops gene edited plant traits | Health Technology |
New Ventures Select LLC
 New Ventures Select LLC Investment ManagersFinance Functions as a venture capital fund | Finance |
University of Virginia
 University of Virginia Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Virginia National Bank (Charlottesville)
 Virginia National Bank (Charlottesville) Major BanksFinance Operates as a national chartered bank | Finance |
The College of William & Mary
 The College of William & Mary Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The RF&P Corp.
 The RF&P Corp. Other Consumer ServicesConsumer Services Provides railroad transportation services | Consumer Services |
Cibus US LLC
Cibus US LLC BiotechnologyHealth Technology Develops products in agriculture and specialty chemicals | Health Technology |
Cibus, Inc.
 Cibus, Inc. Information Technology ServicesTechnology Services Operates as an agricultural technology company | Technology Services |
Cibus Ltd.
Cibus Ltd. BiotechnologyHealth Technology Engages in the research and development of plant gene editing technology | Health Technology |
Vantage Consulting Group, Inc.
Vantage Consulting Group, Inc. Investment ManagersFinance Vantage strives to deliver a comprehensive, bespoke investment solution firmly grounded in fundamental investment principles. At the core of this solution lies an investment strategy meticulously tailored to their clients’ unique investment objectives, risk tolerances, diversification preferences, and their specific liquidity needs and investment horizons. | Finance |
New Ventures III LLC
New Ventures III LLC Investment ManagersFinance Acts as Venture Capital Fund | Finance |
Enterin, Inc.
Enterin, Inc. BiotechnologyHealth Technology Develops novel compounds that dysfunctional gut-brain axis in patients with neurodegenerative disease | Health Technology |
New Ventures II LLC
New Ventures II LLC Investment ManagersFinance Functions as a venture capital fund | Finance |
